Widespread use of gene therapy technologies is limited in part by the lack of small genetic
switches with wide dynamic ranges that control transgene expression without the …

One of the biggest challenges in optimizing viral vectors for gene therapy relates to the
immune response of the host. Adeno-associated virus (AAV) vectors are associated with low …

Over 15 years after hepatotoxicity was first observed following administration of an adeno-
associated virus (AAV) vector during a hemophilia B clinical trial, recent reports of treatment …

Adeno-associated virus (AAV) vectors are associated with relatively mild host immune
responses in vivo. Although AAV induces very weak innate immune responses, neutralizing …

Robust synthetic devices are requisite for the construction of synthetic genetic circuits and
important scientific and technological tools to control cellular processes. We developed …

Researchers have conducted numerous pre-clinical and clinical gene transfer studies using
recombinant viral vectors derived from a wide range of pathogenic viruses such as …

Numerous preclinical studies have demonstrated the efficacy of viral gene delivery vectors,
and recent clinical trials have shown promising results. However, the tight control of …

Synthetic transcription factors (synTFs) that control beneficial transgene expression are an
important method to increase the safety and efficacy of cell and gene therapy. Reliance on …

Lentiviral vectors have been used extensively as gene transfer tools for the central nervous
system throughout the past decade since they transduce most cell types in the brain …

It is hoped that the use of gene transfer technology to treat both monogenetic and acquired
diseases may soon become a common therapy option in medicine. For gene therapy to …